Merck decides it's smart to leave ALEC

Another drug company is bailing on ALEC, the group that gets business leaders together with mostly Republican state lawmakers to write so-called model legislation, generally around business. The American Legislative Exchange Council has been in the spotlight this year for support of tougher voter ID laws and self-defense gun laws. A Merck ($MRK) spokeswoman tells that Merck reviews its memberships each fall and decides which ones meet its budget and policy priorities, and ALEC didn't make the cut this year. Johnson & Johnson ($JNJ) dropped its membership in June. Pfizer found itself the subject of criticism earlier this year for its membership in ALEC, which has been accused of inappropriate lobbying. Story | More

Suggested Articles

Pfizer's diagnosis-focused launch strategy for Vyndaqel and Vyndamax is paying off with the meds reaching thousands of patients already.

Pfizer terminated a slew of trial cohorts testing Bavencio in combination with its own experimental drugs, as well as one monotherapy trial.

With its Eli Lilly-partnered Olumiant nearing filing in atopic dermatitis, Incyte's other JAK med Jakafi is also looking for a win in that indication.